Skip to main content
. Author manuscript; available in PMC: 2013 Aug 13.
Published in final edited form as: J Am Coll Cardiol. 2011 May 27;58(1):73–82. doi: 10.1016/j.jacc.2010.12.044

Figure 7. SS-31 ameliorated cardiac hypertrophy and failure in Gαq overexpressing mice.

Figure 7

Echocardiography of Gαq mice 16 weeks of age. (A) SS-31 (3mg/kg/d) for 4 weeks (from age 12–16 weeks) significantly ameliorated the decline in systolic function, as indicated by FS in Gαq mice. (B,C) Chamber enlargement and diastolic dysfunction in Gαq mice were slightly attenuated by SS-31 with a statistical trend, p=0.08 and 0.06, respectively. (D) Worsening of myocardial performance index (MPI) in Gαq mice was significantly ameliorated by SS-31. (E) An increase in normalized heart weight in Gαq mice was substantially protected by SS-31, while there was a trend towards protection from increased normalized lung weight by SS-31 (p=0.09), n=3–6.